341 related articles for article (PubMed ID: 23116806)
1. Characterization of hepatic lesions (≤ 30 mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging.
Takahashi M; Maruyama H; Shimada T; Kamezaki H; Sekimoto T; Kanai F; Yokosuka O
Eur J Radiol; 2013 Jan; 82(1):75-84. PubMed ID: 23116806
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma.
Numata K; Fukuda H; Miwa H; Ishii T; Moriya S; Kondo M; Nozaki A; Morimoto M; Okada M; Takebayashi S; Maeda S; Nozawa A; Nakano M; Tanaka K
Eur J Radiol; 2014 Jan; 83(1):95-102. PubMed ID: 24176532
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis.
Kim HY; Choi JY; Kim CW; Bae SH; Yoon SK; Lee YJ; Rha SE; You YK; Kim DG; Jung ES
Liver Transpl; 2012 Jul; 18(7):850-7. PubMed ID: 22407909
[TBL] [Abstract][Full Text] [Related]
4. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
5. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
6. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
[TBL] [Abstract][Full Text] [Related]
8. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
Kim JE; Kim SH; Lee SJ; Rhim H
AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
[TBL] [Abstract][Full Text] [Related]
9. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
Park MJ; Kim YK; Lee MH; Lee JH
Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
[TBL] [Abstract][Full Text] [Related]
11. Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas.
Goshima S; Kanematsu M; Watanabe H; Kondo H; Mizuno N; Kawada H; Shiratori Y; Onozuka M; Moriyama N; Bae KT
Eur J Radiol; 2011 Aug; 79(2):e108-12. PubMed ID: 21592707
[TBL] [Abstract][Full Text] [Related]
12. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
[TBL] [Abstract][Full Text] [Related]
13. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.
Frericks BB; Loddenkemper C; Huppertz A; Valdeig S; Stroux A; Seja M; Wolf KJ; Albrecht T
AJR Am J Roentgenol; 2009 Oct; 193(4):1053-60. PubMed ID: 19770329
[TBL] [Abstract][Full Text] [Related]
14. Timing of the hepatic arterial phase at Gd-EOB-DTPA-enhanced hepatic dynamic MRI: comparison of the test-injection and the fixed-time delay method.
Nakamura S; Nakaura T; Kidoh M; Utsunomiya D; Doi Y; Harada K; Uemura S; Yamashita Y
J Magn Reson Imaging; 2013 Sep; 38(3):548-54. PubMed ID: 23744782
[TBL] [Abstract][Full Text] [Related]
15. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreiländertreffen 2008, Davos.
Seitz K; Strobel D; Bernatik T; Blank W; Friedrich-Rust M; Herbay Av; Dietrich CF; Strunk H; Kratzer W; Schuler A
Ultraschall Med; 2009 Aug; 30(4):383-9. PubMed ID: 19688670
[TBL] [Abstract][Full Text] [Related]
16. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis.
Xu PJ; Yan FH; Wang JH; Lin J; Ji Y
J Magn Reson Imaging; 2009 Feb; 29(2):341-9. PubMed ID: 19161186
[TBL] [Abstract][Full Text] [Related]
17. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.
Yoo HJ; Lee JM; Lee JY; Kim SH; Kim SJ; Han JK; Choi BI
Invest Radiol; 2009 Dec; 44(12):800-7. PubMed ID: 19838119
[TBL] [Abstract][Full Text] [Related]
18. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines.
Golfieri R; Garzillo G; Ascanio S; Renzulli M
Dig Dis; 2014; 32(6):696-704. PubMed ID: 25376286
[TBL] [Abstract][Full Text] [Related]
19. Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis.
Kim YK; Lee YH; Kwak HS; Kim CS; Han YM
Clin Imaging; 2008; 32(6):453-9. PubMed ID: 19006774
[TBL] [Abstract][Full Text] [Related]
20. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.
Kim SH; Kim SH; Lee J; Kim MJ; Jeon YH; Park Y; Choi D; Lee WJ; Lim HK
AJR Am J Roentgenol; 2009 Jun; 192(6):1675-81. PubMed ID: 19457834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
